Invention Grant
- Patent Title: Mutant calreticulin for the diagnosis of myeloid malignancies
-
Application No.: US15021906Application Date: 2014-09-15
-
Publication No.: US10344335B2Publication Date: 2019-07-09
- Inventor: Robert Kralovics , Thorsten Klampfl , Heinz Gisslinger
- Applicant: CEMM—FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH
- Applicant Address: AT Vienna
- Assignee: CEMM—Forschungszentrum für Molekulare Medizin GmbH
- Current Assignee: CEMM—Forschungszentrum für Molekulare Medizin GmbH
- Current Assignee Address: AT Vienna
- Agency: Inhouse Patent Counsel, LLC
- Agent Michele M. Wales
- Priority: EP13184632 20130916; EP13186939 20131001
- International Application: PCT/EP2014/069638 WO 20140915
- International Announcement: WO2015/036599 WO 20150319
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C12Q1/6886 ; G01N33/574 ; A61K39/00 ; C07K14/47 ; C07K16/18 ; C12N15/113
Abstract:
The present invention relates to a method for diagnosing myeloid malignancy comprising determining the presence of a mutant allele of the calreticulin gene. Also genomic sequences, cDNA sequences, mRNA sequences and protein sequences of the mutant calreticulin are subject of the present invention. Further, the invention relates to medical uses of inhibitors of mutant calreticulin.
Public/Granted literature
- US20160251723A1 MUTANT CALRETICULIN FOR THE DIAGNOSIS OF MYELOID MALIGNANCIES Public/Granted day:2016-09-01
Information query
